May 25, 2026 03:33AM
May 15, 2026 02:55AM
May 8, 2026 02:48AM
May 8, 2026 02:48AM
May 8, 2026 02:47AM
Mar 23, 2026 03:50AM
Feb 6, 2026 06:17AM Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
Aug 25, 2025 03:26AM
May 15, 2025 04:56AM
Apr 1, 2025 06:14AM
Mar 25, 2025 03:08AM
Mar 3, 2025 03:17AM
Feb 28, 2025 08:11AM
Feb 18, 2025 02:13AM Leqembi® sales reaches €200 million - first sales milestone achieved
Jan 31, 2025 07:12AM
Jan 26, 2025 09:50PM
Jan 13, 2025 09:49PM
Oct 31, 2024 07:43PM
Jun 9, 2024 10:55PM
Jun 10, 2023 07:34AM
Jun 7, 2023 11:02PM Marketing Authorization Application for lecanemab as treatment for early Alzheimer's disease filed in South Korea
May 21, 2023 11:01PM
May 16, 2023 11:19PM
May 15, 2023 11:01PM
Apr 3, 2023 10:48PM
Apr 3, 2023 02:19AM
Mar 31, 2023 02:14AM
Mar 19, 2023 10:43PM Eisai publishes societal value of lecanemab using phase 3 Clarity AD data in peer-reviewed Neurology and Therapy journal
Mar 13, 2023 11:01PM
Mar 5, 2023 09:50PM
Dec 22, 2022 09:44PM
Nov 29, 2022 10:34PM
Nov 29, 2022 10:15PM
Nov 21, 2022 03:40AM
Sep 27, 2022 11:10PM Lecanemab phase 3 Clarity AD study in early Alzheimer's disease meets primary and all key secondary endpoints with high statistical significance
Aug 5, 2022 02:14AM
Jul 26, 2022 02:16AM
Jul 5, 2022 11:04PM
May 9, 2022 10:42PM
Sep 27, 2021 11:01PM

15,435 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All